European Medicines Agency (EMA) launches public consultation on draft guideline on registry-based studies
The new draft guidance aims to optimise the use of registry-based studies as a source of real-world evidence. It addresses methodological, legal and operational aspects in the use of registry-based studies to support regulatory decision-making.
Source:
European Medicines Agency